Alimera Sciences (NASDAQ:ALIM) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on ALIM. Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, HC Wainwright lowered Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a report on Tuesday, June 25th.

Alimera Sciences Stock Performance

NASDAQ ALIM opened at $5.54 on Monday. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.79 and a quick ratio of 2.62. The business has a 50 day moving average price of $5.55 and a 200 day moving average price of $4.50. The company has a market capitalization of $290.24 million, a P/E ratio of -3.53 and a beta of 1.25. Alimera Sciences has a 1-year low of $2.61 and a 1-year high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The company had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.76 million. Sell-side analysts expect that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

A number of institutional investors have recently added to or reduced their stakes in ALIM. Renaissance Technologies LLC grew its holdings in Alimera Sciences by 3.9% during the 2nd quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after acquiring an additional 6,900 shares during the period. Rhumbline Advisers acquired a new stake in Alimera Sciences during the 2nd quarter worth $113,000. Fifth Lane Capital LP acquired a new stake in Alimera Sciences during the 1st quarter worth $83,000. Hillsdale Investment Management Inc. acquired a new stake in Alimera Sciences during the 1st quarter worth $169,000. Finally, Bank of New York Mellon Corp acquired a new stake in Alimera Sciences during the 2nd quarter worth $344,000. 99.83% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).